Phathom Pharmaceuticals unveils commercial strategy momentum at Jefferies conference

Phathom Pharmaceuticals unveils commercial strategy momentum at Jefferies conference
Phathom unveils GI strategy momentum

Phathom Pharmaceuticals has made available the replay of its recent fireside chat at the Jefferies Global Healthcare Conference. President and CEO Steve Basta and Chief Financial and Business Officer Sanjeev Narula addressed the company's recent business momentum and outlined its commercial strategy centered on gastrointestinal treatments.

The presentation highlights how Phathom Pharmaceuticals is advancing its position in the GI market. Investors and industry stakeholders can now access the recording for more insights into the company's strategic priorities and current performance.

Phathom has been active on the investor conference circuit in recent months, participating in a series of events during May and June to share business updates with stakeholders, according to a recent announcement. The company also continues to honor the legacy of founder Dr. Tachi Yamada and his contributions to GI medicine, as noted in an earlier company statement. These activities provide further context to Phathom’s ongoing focus in the gastrointestinal sector.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.